J&J Unit Under Scrutiny For Alleged Off-Label Marketing

Law360, New York (August 8, 2006, 12:00 AM EDT) -- Johnson & Johnson said in a U.S. Security and Exchange Commission filing Tuesday that one of its subsidiaries has received a subpoena related to the alleged off-label marketing of its epilepsy and migraine drug Topamax.

J&J said it was cooperating with the recent subpoena, which it received in June.

This is not the first time the company has come under fire for alleged off-label marketing of the drug.

In December 2003, J&J subsidiary Ortho-McNeil Pharmaceutical Inc. received its first subpoena from the U.S. Attorney’s Office for...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.